Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 14, 2007

Primary Completion Date

March 5, 2020

Study Completion Date

March 5, 2020

Conditions
Diffuse Large Cell LymphomaLymphoma
Interventions
DRUG

Zevalin

(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.

DRUG

Carmustine

300 mg/m\^2 by vein.

DRUG

Etoposide

200 mg/m\^2 by vein every 12 hours.

DRUG

Cytarabine

200 mg/m\^2 by vein every 12 hours.

DRUG

Melphalan

140 mg/m\^2 by vein.

DRUG

Rituximab

"Arm 1, Arm 2 = 250 mg/m\^2 by vein;~Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;~Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy."

PROCEDURE

Stem Cell Transplant

Injection of stem cells (Autologous SCT)

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00591630 - Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | Biotech Hunter | Biotech Hunter